Market Closed -
Nasdaq
04:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
1.32
USD
|
-0.75%
|
|
-5.71%
|
-29.79%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
184.4
|
66.28
|
123.9
|
86.96
|
-
|
-
|
Enterprise Value (EV)
1 |
-27.11
|
-73.52
|
-16.84
|
49.58
|
-179.3
|
-15.61
|
P/E ratio
|
-0.37
x
|
-0.93
x
|
-0.95
x
|
-0.94
x
|
-1.02
x
|
-1.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
58
x
|
0.01
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-120
x
|
-0
x
|
EV / EBITDA
|
0.66
x
|
-
|
0.18
x
|
-0
x
|
0
x
|
0
x
|
EV / FCF
|
0.66
x
|
1.22
x
|
-
|
-0.81
x
|
1.72
x
|
0.13
x
|
FCF Yield
|
150%
|
82.2%
|
-
|
-123%
|
58.3%
|
765%
|
Price to Book
|
0.87
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,815
|
28,815
|
65,881
|
65,881
|
-
|
-
|
Reference price
2 |
6.400
|
2.300
|
1.880
|
1.320
|
1.320
|
1.320
|
Announcement Date
|
3/31/22
|
3/14/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.5
|
10,120
|
EBITDA
1 |
-
|
-41.23
|
-
|
-91.38
|
-95,892
|
-121,887
|
-166,196
|
EBIT
1 |
-
|
-41.23
|
-71.42
|
-91.44
|
-87.1
|
-125.3
|
-136.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-8,356.63%
|
-1.35%
|
Earnings before Tax (EBT)
1 |
-
|
-67.81
|
-70.71
|
-85.23
|
-84
|
-120.1
|
-131.3
|
Net income
1 |
-14.59
|
-74.99
|
-71.33
|
-86.08
|
-84.4
|
-120.1
|
-131.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-8,003.8%
|
-1.3%
|
EPS
2 |
-82.36
|
-17.30
|
-2.480
|
-1.980
|
-1.398
|
-1.298
|
-1.252
|
Free Cash Flow
1 |
-
|
-40.8
|
-60.42
|
-
|
-61
|
-104.5
|
-119.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,966.67%
|
-1.18%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/9/21
|
3/31/22
|
3/14/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.4
|
-17.01
|
-18.16
|
-15.86
|
-20.39
|
-17.92
|
-21.85
|
-23.48
|
-28.18
|
-20.2
|
-21.2
|
-22.3
|
-23.4
|
-31.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.24
|
-17.14
|
-18.39
|
-15.57
|
-19.61
|
-16.64
|
-20.65
|
-22.12
|
-25.83
|
-19.04
|
-20.3
|
-21.6
|
-23
|
-28.9
|
Net income
1 |
-21.24
|
-17.2
|
-18.5
|
-15.69
|
-19.94
|
-17.04
|
-21.18
|
-21.68
|
-26.18
|
-19.46
|
-20.3
|
-21.6
|
-23
|
-28.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.330
|
-0.6000
|
-0.6400
|
-0.5400
|
-0.6900
|
-0.5900
|
-0.7400
|
-0.4300
|
-0.4000
|
-0.3000
|
-0.3100
|
-0.3300
|
-0.3500
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/16/22
|
8/11/22
|
11/9/22
|
3/14/23
|
5/11/23
|
8/11/23
|
11/13/23
|
3/5/24
|
5/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
212
|
140
|
141
|
37.4
|
266
|
103
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-40.8
|
-60.4
|
-
|
-61
|
-105
|
-120
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-63.3%
|
-107,847%
|
-78,359%
|
-86,813%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
7.350
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.69
|
-
|
-
|
-
|
2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
0.02%
|
Announcement Date
|
8/9/21
|
3/31/22
|
3/14/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
1.32
USD Average target price
9.75
USD Spread / Average Target +638.64% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.79% | 86.96M | | +64.92% | 62.86B | | -1.85% | 41.38B | | +45.89% | 40.38B | | -8.93% | 27.64B | | +13.05% | 26.46B | | -21.96% | 18.9B | | +4.21% | 12.67B | | +25.74% | 12.27B | | +27.42% | 12.07B |
Other Biotechnology & Medical Research
|